兩面針(600249.SH):建設院士工作站通過備案
格隆匯8月14日丨兩面針(600249.SH)公佈,公司於近日收到廣西科學技術廳《關於2025年度第二批廣西院士工作站備案名單的通知》,公司建設院士工作站通過備案。
爲充分發揮院士專家對科技創新發展的推動作用,搭建科技合作和交流平臺,提升創新能力。公司、杜如虛院士、廣東健齒生物科技有限公司(以下簡稱“健齒生物”)三方簽署了《共同組建院士工作站合作協議》。杜如虛院士爲中國香港籍,博士、教授、加拿大工程院院士,國際製造工程師學會院士,美國機械工程師學會院士,國家級高層次人才,廣東省科技領軍人才,香港工程師協會院士,健齒生物首席科學家。健齒生物是具有國家二類、三類醫遼器械資質的省級專精特新企業、高新技術企業,同時擁有牙種植體和個性化基臺三類註冊證的企業。三方以共同組建的院士工作站爲基礎,圍繞口腔行業發展需要及國內外技術發展趨勢,共同研究口腔疾病預防、口腔健康服務等方面的關鍵技術。探索應用人工智能技術研發口腔護理用品,培養科技創新人才,提高企業的自主創新能力和核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.